Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

CAMBRIDGE, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti ...

(RTTNews) - Biogen Inc. (BIIB) announced that results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in individuals with IgA nephropathy or ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies ...

Biogen acquired the rights to felzartamab, which is already in Phase 3 studies in late antibody-mediated rejection in adult kidney transplant recipients and in IgA nephropathy, as part of last ...

IgA levels declined for 19 months after the last felzartamab dose, and IgG recovered by 6-9 months. Treatment-emergent adverse events were typically grade 1 or 2 and were not dose-dependent.

Patients receiving nine-dose regimen over five months experienced deep and durable reduction in proteinuria, reaching up to ~50% mean reduction in UPCR at end of study at month 24 and ...

Patients receiving nine-dose regimen over five months experienced deep and durable reduction in proteinuria, reaching up to ~50% mean reduction in UPCR at end of study at month 24 and over 18 ...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy GlobeNewswire 5d Nasdaq Composite hits record high; See Nasdaq-100's 10 best and worst YTD performers ...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 Oct. 26, 2024 8:15 PM ET Biogen Inc. (BIIB) ...